Please login to the form below

Not currently logged in
Email:
Password:

Akcea Therapeutics

This page shows the latest Akcea Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: setback for Akcea/Ionis, Urovant adds gene therapy, Metrion gains funding

Daily Brief: setback for Akcea/Ionis, Urovant adds gene therapy, Metrion gains funding

FDA surprises Akcea and Ionis with rejection of Waylivra. Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, has been knocked back by a surprise rejection via a Complete Response Letter (CRL) from ... Paula Soteropoulos. Akcea’s CEO Paula

Latest news

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics